Completed PHASE2 INTERVENTIONAL 1-arm NCT05576597

Effect of Butyrate Supplement on Rheumatoid Arthritis

A Pilot Study to Evaluate Efficacy and Safety of Butyrate Supplement in the Treatment of Rheumatoid Arthritis

Sponsor: Peking University People's Hospital

Updated 3 times since 2022 Last updated: Aug 20, 2024 Started: Aug 23, 2022 Primary completion: Oct 1, 2023 Completion: Jun 15, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05576597, this PHASE2 trial focuses on Rheumatoid Arthritis and remains completed. Sponsored by Peking University People's Hospital, it has been updated 3 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2

Status: Recruiting → Completed
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Nov 2022 — Jul 2024 [monthly]

Recruiting PHASE2

First recorded

Aug 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Peking University People's Hospital

Data source: Peking University People's Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China